OptiMesh® HA Nano
Designed to Ignite Osseointegration
The OptiMesh HA Nano technology offers a well-studied nano-thin surface treatment. This technology is designed to create an ultra-hydrophilic absorption environment that promotes rapid cellular activity and creates a 3D bioactive surface, all intended to accelerate osseointegration and reduce potential infection risks.
Referenced effects are based on the presence of the HA Nano surface treatment as confirmed by various studies. Studies may have been performed on different base materials than OptiMesh.
OptiMesh®
Conforms to You
The only conforming, patient specific expandable implant on the market, OptiMesh is delivered through one of the smallest insertion profiles, dynamically conforms to a patient’s unique endplate morphology, and powerfully expands to one of the largest implant footprints available.*
Natural Restoration and Expansion Power
OptiMesh’s powerful distraction forces and conformance to the endplates provide strength and stability to restore disc height, achieve alignment goals, and promote a robust fusion.1
Strength through Granular Mechanics
Compaction of the proprietary fill material creates a robust platform for restoration of disc height and alignment, and promotes a robust biologic environment for fusion.
OptiMesh
Unparalleled Versatility
Open
TLIF/PLIF
MIS
TLIF
Ultra-MIS
OptiLIF®
Ultra-MIS
OptiLIF® Endo
A single implant may be used for multiple lumbar fusion approaches accommodating patient specific needs. No matter your approach to lumbar fusion, OptiMesh provides a best in class expandable interbody solution from Open, MIS TLIF, ultra-MIS (OptiLIF), to endoscopic fusion (OptiLIF Endo) applications.
Ultra-Minimally Invasive Delivery, Maximal Patient Outcomes
OptiMesh’s ultra-minimally invasive delivery is designed to provide patients with the benefits of MIS surgery through a reproducible, efficient procedure, without sacrificing, but maximizing footprint coverage. Published clinical results show improved patient outcomes, such as:
[1] Lavoie S, Bydon M, Nunley P, Sandhu F, Shore J, Stone M. Does indirect decompression vs open decompression in percutaneous interbody fusion provide better results? An ad-hoc analysis of a prospective multi-center percutaneous interbody fusion study. International Society for the Advancement of Spine Surgery (ISASS) Annual Conference 2021. Miami, FL. 2021 May 13-15.
[2] Chi J, Nunley P, et al. Two-Year Outcomes From a Prospective Multicenter Investigation Device Trial of a Novel Conformal Mesh Interbody Fusion Device. Int J Spine Surg. 2021 Dec; 15(6): 1103-1114.
* Data on file
Unmatched Clinical Experience
The SCOUT IDE Study
Unique in design and in published data, OptiMesh holds the highest achievement in clinical validation with an IDE De Novo level grant. Spineology Clinical Outcomes Trial (SCOUT Study): IDE trial of a novel, conformable device placed in the disc space through a small portal and filled with bone graft in-situ. At 24 months:
0%
98% fusion at 12 months post-op, evaluated by two independent radiologists.0%
85% of patients experienced a clinically meaningful reduction in back pain at 3 months.0%
75% of patients experienced a clinically meaningful improvement in back function at 3 months.0%
92% of patients rated their satisfaction "excellent" or "good" at 6 months.Chi J, Nunley P, et al. Two-Year Outcomes From a Prospective Multicenter Investigation Device Trial of a Novel Conformal Mesh Interbody Fusion Device. Int J Spine Surg. 2021 Dec; 15(6): 1103-1114.
Unique in Data
20 Clinical Publications
> 50,000 implants
Additionally, 20+ years of clinical experience, 20 clinical publications, and > 50,000 devices implanted set OptiMesh alone in the interbody fusion space.
Spineology
In the News
Read the most important updates and news about Spineology® in the following posts, then click to learn more about us and our growing product and team.
